Drugs Used In Diabetes Flashcards
Lispro
Rapid-acting:Insulin
Insulins
Rapid-acting: Lispro, aspart, glulisine
Short-acting: Regular
Intermediate-acting: NPH
Long-acting: Detemir, glargine
aspart
Rapid-acting:Insulin
glulisine
Rapid-acting:Insulin
Regular
Short-acting:Insulin
NPH
Intermediate-acting: Insulin
Detemir
Long-acting: Insulin
glargine
Long-acting: Insulin
Rapid-acting:insulin
Lispro
aspart
glulisine
Short-acting:Insulin
Regular
Intermediate-acting: Insulin
NPH
Long-acting: Insulin
Detemir
Glargine
Insulins
Mechanism of action
Activate insulin receptor
Activate insulin receptor
Insulins
Mechanism of action
Insulins
Effects
Reduce circulating glucose
Promote glucose transport and oxidation;glycogen, lipid, protein synthese; and regulation of gene expression
Reduce circulating glucose
Promote glucose transport and oxidation;glycogen, lipid, protein synthese; and regulation of gene expression
Insulins
Effects
Insulins
Clinical applications
Type 1 and type 2 diabetes
Type 1 and type 2 diabetes
Insulins
Clinical applications
Insulins
Toxicity
Hypoglycemia
Weight gain
Lipodystrophy (rare)
Hypoglycemia
Weight gain
Lipodystrophy (rare)
Insulins
Toxicity
Sulfonylureas
Glipizide
Glyburide
Glimepiride
Glipizide
Sulfonylurea
Glyburide
Sulfonylurea
Glimepiride
Sulfonylurea
Sulfonylurea
Mechanism of action
Insulin secretagogues: close K+ Channels in beta cells
Increase insulin release
Insulin secretagogues: close K+ Channels in beta cells
Increase insulin release
Sulfonylurea
Mechanism of action
Sulfonylurea
Effects
In patients with functioning beta cells, reduce circulating glucose
Increase glycogen, fat, and protein formation
Gene regulation
In patients with functioning beta cells, reduce circulating glucose
Increase glycogen, fat, and protein formation
Gene regulation
Sulfonylurea
Effects
Sulfonylurea
Clinical applications
Type 2 diabetes
Sulfonylurea
Clinical applications
Type 2 diabetes
Sulfonylurea
Toxicity
Hypoglycemia
Weight gain
Hypoglycemia
Weight gain
Sulfonylurea
Toxicity
Glitinides
Repaglinide
Nateglinide
Repaglinide
Glitinide
Nateglinide
Glitinide
Repaglinide
Mechanism of action
Insulin secretagogue: similar to sulfonylureas with some overlap in binding sites
Insulin secretagogue: similar to sulfonylureas with some overlap in binding sites
Repaglinide
Nateglinide
Mechanism of action
Nateglinide
Mechanism of action
Insulin secretagogue: similar to sulfonylureas with some overlap in binding sites
Repaglinide
Effects
In patients with functioning beta cells, reduces circulating glucose
Increases glycogen, fat, and protein formation
Gene regulation
In patients with functioning beta cells, reduces circulating glucose
Increases glycogen, fat, and protein formation
Gene regulation
Repaglinide (glitinides) Nateglinide (glitinides) Glipizide (sulfonylurea) Glyburide (sulfonylurea) Glimepiride (sulfonylurea) Effects
Biguanide
Metformin
Metformin
Biguanide
Metformin (Biguanide)
Mechanism of action
Obscure: Reduced hepatic and renal gluconeogenesis
Obscure: Reduced hepatic and renal gluconeogenesis
Metformin (Biguanide)
Mechanism of action
Metformin (Biguanide)
Effects
Decreased endogenous glucose production
Decreased endogenous glucose production
Metformin (Biguanide)
Effects
Alpha-glucosidase inhibitors
Acarbose
Miglitol
Acarbose
Alpha-glucosidase inhibitor
Miglitol
Alpha-glucosidase inhibitor
Alpha-glucosidase inhibitors
Mechanism of action
Inhibit intestinal a-glucosidases
Inhibit intestinal a-glucosidases
Alpha-glucosidase inhibitors
Mechanism of action
Alpha-glucosidase inhibitors
Effects
Reduces conversion of starch and disaccharides to monosaccharides
Reduces postpradial hyperglycemia
Reduces conversion of starch and disaccharides to monosaccharides
Reduces postpradial hyperglycemia
Alpha-glucosidase inhibitors
Effects
Thiazolidinediones
Pioglitazone
Rosiglitazone
Pioglitazone
Thiazolidinedione
Rosiglitazone
Thiazolidinedione
Pioglitazone
Mechanism of action
Regulates gene expression by binding PPAR-y and PPAR-a
Rosiglitazone
Mechanism of action
Regulates gene expression by binding PPAR-y
Regulates gene expression by binding PPAR-y
Rosiglitazone
Mechanism of action
Regulates gene expression by binding PPAR-y and PPAR-a
Pioglitazone
Mechanism of action
Pioglitazone
Rosiglitazone
Effects
Reduces insulin resistance
Reduces insulin resistance
Pioglitazone
Rosiglitazone
Effects
Glucagon-like polypeptide-1 (GLP-1) receptor agonists
Exenatide
Liraglutide
Exenatide
Glucagon-like polypeptide-1 (GLP-1) receptor agonist
Liraglutide
Glucagon-like polypeptide-1 (GLP-1) receptor agonist
Exenatide (GLP-1)
Mechanism of action
Analog of GLP-1: binds to GLP-1 receptors
Analog of GLP-1: binds to GLP-1 receptors
Exenatide
Liraglutide
Mechanism of action
Exenatide
Liraglutide
Effects
Reduces post-meal glucose excursion: increases glucose-mediated insulin release, lowers glucagon levels, slows gastric emptying, decreases appetite
Reduces post-meal glucose excursion: increases glucose-mediated insulin release, lowers glucagon levels, slows gastric emptying, decreases appetite
Exenatide
Liraglutide
Effects
Dipeptidyl peptidase-4 (DPP-4) inhibitors
Sitagliptin
Saxagliptin
Linagliptin
Sitagliptin
Dipeptidyl peptidase-4 (DPP-4) inhibitor
Saxagliptin
Dipeptidyl peptidase-4 (DPP-4) inhibitor
Linagliptin
Dipeptidyl peptidase-4 (DPP-4) inhibitor
Sitagliptin
Saxagliptin
Linagliptin
Mechanism of action
DPP-4 inhibitor: blocks degradation of GLP-1, raises circulating GLP-1 levels
DPP-4 inhibitor: blocks degradation of GLP-1, raises circulating GLP-1 levels
Sitagliptin
Saxagliptin
Linagliptin
Mechanism of action
Sitagliptin
Saxagliptin
Linagliptin
Effects
Reduces post-meal glucose excursion: increases glucose-mediated insulin release, lowers glucagon levels, slows gastric emptying, decreases appetite
Reduces post-meal glucose excursion: increases glucose-mediated insulin release, lowers glucagon levels, slows gastric emptying, decreases appetite
Sitagliptin
Saxagliptin
Linagliptin
Exenatide
Effects